Nonalcoholic fatty liver disease and type 2 diabetes: pathophysiological mechanisms shared between the two faces of the same coin
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
The pathophysiological mechanisms underlying the close relationship between nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM) are multiple, complex and only partially known. The purpose of this paper was to review the current knowledge of these mechanisms in a unified manner. Subjects with NAFLD and T2DM have established insulin resistance (IR), which exacerbates the two comorbidities. IR worsens NAFLD by increasing the accumulation of free fatty acids (FFAs) in the liver. This occurs due to an increase in the influx of FFAs from peripheral adipose tissue by the activation of hormone-sensitive lipase. In addition, there is de novo increased lipogenesis, a transcription factor, the sterols regulatory element-binding transcription factor 1c (SREBP-1c), which activates the expression of several genes strongly promotes lipogenesis by the liver and facilitate storage of triglycerides. Lipids accumulation in the liver induces a chronic stress in the endoplasmic reticulum of the hepatocytes. Genome-wide association studies have identified genetic variants associated with NAFLD severity, but unrelated to IR. In particular, the alteration of patatin-like phospholipase domain-containing protein 3 contributes to the susceptibility to NAFLD. Furthermore, the lipotoxicity of ceramides and diacylglycerol, well known in T2DM, triggers a chronic inflammatory process favoring the progression from hepatic steatosis to steatohepatitis. Reactive oxygen species produced by mitochondrial dysfunction trigger both liver inflammation and beta-cells damage, promoting the progression of both NAFLD and T2DM. The close association between NAFLD and T2DM is bidirectional, as T2DM may trigger both NAFLD onset and its progression, but NAFLD itself may contribute to the development of IR and T2DM. Future studies on the mechanisms will have to deepen the knowledge of the interaction between the two pathologies and should allow the identification of new therapeutic targets for the treatment of NAFLD, currently substantially absent.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Eslam, M., Newsome, P. N., Sarin, S. K., Anstee, Q. M., Targher, G., Romero-Gomez, M., Zelber-Sagi, S., Wai-Sun Wong, V., Dufour, J.-F., Schattenberg, J. M., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.039 · Cited by 4,472
Functional interactions between the gut microbiota and host metabolism
Tremaroli, V., & Bäckhed, F. (2012) · Nature · doi:10.1038/nature11552 · Cited by 4,387 · cited 3×
“Patatin-like phospholipase domain-containing protein 3 (PNPLA3), TM6SF2 and apolipoprotein C3 (APOC3) So far, it seems clear that IR plays a key role in worsening both T2DM and NAFLD.”
BackgroundSteatohepatitis: A tale of two “hits”?
Day, C. P., & James, O. F. W. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70599-2 · Cited by 4,285
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L. A., Boerwinkle, E., Cohen, J. C., & Hobbs, H. H. (2008) · Nature Genetics · doi:10.1038/ng.257 · Cited by 3,416
Cloning of adiponectin receptors that mediate antidiabetic metabolic effects
Yamauchi, T., Kamon, J., Ito, Y., Tsuchida, A., Yokomizo, T., Kita, S., Sugiyama, T., Miyagishi, M., Hara, K., Tsunoda, M., et al. (2003) · Nature · doi:10.1038/nature01705 · Cited by 3,176 · cited 1×
“Once secreted, it is able to bind its two trans-membrane receptors, AdipoR1 and AdipoR2, mainly expressed at the level of skeletal muscle and liver [85].”
BackgroundMacrophages, inflammation, and insulin resistance
Olefsky, J. M., & Glass, C. K. (2010) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021909-135846 · Cited by 2,733
Nonalcoholic Fatty Liver Disease
Marchesini, G., Brizi, M., Bianchi, G., Tomassetti, S., Bugianesi, E., Lenzi, M., McCullough, A. J., Natale, S., Forlani, G., & Melchionda, N. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1844 · Cited by 2,581 · cited 1×
“Both NAFLD and T2DM patients share the same qualitative and quantitative multi-organ IR patterns, affecting not only glucose metabolism but also fatty acids and amino acid metabolism that is typical of the patient with overt T2DM [7].”
BackgroundEndocrine regulation of energy metabolism by the skeleton
Lee, N. K., Sowa, H., Hinoi, E., Ferron, M., Ahn, J. D., Confavreux, C., Dacquin, R., Mee, P. J., McKee, M. D., Jung, D. Y., et al. (2007) · Cell · doi:10.1016/j.cell.2007.05.047 · Cited by 2,554 · cited 1×
“This would suggest that bone have an endocrine regulatory function on glucose homeostasis and, therefore, IR [61].”
BackgroundEvolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis
Tilg, H., & Moschen, A. R. (2010) · Hepatology · doi:10.1002/hep.24001 · Cited by 2,548
Long-term follow-up of patients with NAFLD and elevated liver enzymes
Ekstedt, M., Franzén, L. E., Mathiesen, U. L., Thorelius, L., Holmqvist, M., Bodemar, G., & Kechagias, S. (2006) · Hepatology · doi:10.1002/hep.21327 · Cited by 2,302 · cited 1×
“Patients with NASH, diagnosed by biopsy, were shown to have a 3-folds higher risk of developing T2DM or impaired glucose tolerance [132] and progression to liver fibrosis and cirrhosis was much more evident in patients with IR [139].”
BackgroundLocal and systemic insulin resistance resulting from hepatic activation of IKK-β and NF-κB
Cai, D., Yuan, M., Frantz, D. F., Melendez, P. A., Hansen, L., Lee, J., & Shoelson, S. E. (2005) · Nature Medicine · doi:10.1038/nm1166 · Cited by 2,245
Cornier, M.-A., Dabelea, D., Hernandez, T. L., Lindstrom, R. C., Steig, A. J., Stob, N. R., Van Pelt, R. E., Wang, H., & Eckel, R. H. (2008) · Endocrine Reviews · doi:10.1210/er.2008-0024 · Cited by 2,162 · cited 1×
“This condition appears to be associated with other comorbidities, including a pro-thrombotic status, NAFLD and reproductive disorders [30, 31].”
BackgroundYuan, M., Konstantopoulos, N., Lee, J., Hansen, L., Li, Z.-W., Karin, M., & Shoelson, S. E. (2001) · Science · doi:10.1126/science.1061620 · Cited by 1,884 · cited 1×
“In this case, IKK-β could be a potential therapeutic target for insulin sensitization [58].”
BackgroundIKK-β links inflammation to obesity-induced insulin resistance
Arkan, M. C., Hevener, A. L., Greten, F. R., Maeda, S., Li, Z.-W., Long, J. M., Wynshaw-Boris, A., Poli, G., Olefsky, J., & Karin, M. (2005) · Nature Medicine · doi:10.1038/nm1185 · Cited by 1,773
Molecular mediators of hepatic steatosis and liver injury
Browning, J. D., & Horton, J. D. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200422422 · Cited by 1,772 · cited 2×
“There is an increase in the production of Malonyl-CoA, capable of inhibiting carnitine palmitoyl transferase-1, reducing the influx of fatty acids inflow into the mitochondria and inhibiting the subsequent oxidation of FFAs in hepatocytes [53].”
BackgroundPathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future
Kahn, S. E., Cooper, M. E., & Del Prato, S. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62154-6 · Cited by 1,743
Islet cell failure in type 2 diabetes
Prentki, M. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29103 · Cited by 1,690 · cited 2×
“Thus, the key role of IR in the onset of this condition is evident and the lack of compensation of the beta-cells of IR occurs in the pathogenesis of T2DM [38].”
BackgroundA lipidomic analysis of nonalcoholic fatty liver disease
Puri, P., Baillie, R. A., Wiest, M. M., Mirshahi, F., Choudhury, J., Cheung, O., Sargeant, C., Contos, M. J., & Sanyal, A. J. (2007) · Hepatology · doi:10.1002/hep.21763 · Cited by 1,338 · cited 6×
“These results underline that the type of lipids accumulated in the liver is much more important for altering insulin signaling than for lipid accumulation itself [128].”
BackgroundInfluentialKozlitina, J., Smagris, E., Stender, S., Nordestgaard, B. G., Zhou, H. H., Tybjærg-Hansen, A., Vogt, T. F., Hobbs, H. H., & Cohen, J. C. (2014) · Nature Genetics · doi:10.1038/ng.2901 · Cited by 1,234 · cited 1×
“Glu167Lys causally contributes to NAFLD [100].”
Xu, J., Lloyd, D. J., Hale, C., Stanislaus, S., Chen, M., Sivits, G., Vonderfecht, S., Hecht, R., Li, Y.-S., Lindberg, R. A., et al. (2009) · Diabetes · doi:10.2337/db08-0392 · Cited by 1,151
Rotter, V., Nagaev, I., & Smith, U. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m301977200 · Cited by 1,062
Koliaki, C., Szendroedi, J., Kaul, K., Jelenik, T., Nowotny, P., Jankowiak, F., Herder, C., Carstensen, M., Krausch, M., Knoefel, W. T., et al. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.04.004 · Cited by 1,032 · cited 1×
“During NASH, increased hepatic oxidative stress and oxidative DNA damage are accompanied by a reduced antioxidant defense ability and increased inflammatory response, suggesting “hepatic mitochondrial flexibility” during the early phases of IR, related to obesity and subsequently causing NASH [117].”
BackgroundZhang, X., Yeung, D. C. Y., Karpisek, M., Stejskal, D., Zhou, Z.-G., Liu, F., Wong, R. L. C., Chow, W.-S., Tso, A. W. K., Lam, K. S. L., et al. (2008) · Diabetes · doi:10.2337/db07-1476 · Cited by 908
Hotamisligil, G. S., Budavari, A., Murray, D., & Spiegelman, B. M. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117495 · Cited by 819 · cited 1×
“Some studies have reported that TNF-α is involved in the obesity-related systemic IR by inhibiting insulin receptor tyrosine-kinase in the two tissues primarily responsible of the insulin-induced glucose uptake: muscle and adipose tissue [57].”
BackgroundA small-molecule AdipoR agonist for type 2 diabetes and short life in obesity
Okada-Iwabu, M., Yamauchi, T., Iwabu, M., Honma, T., Hamagami, K.-I., Matsuda, K., Yamaguchi, M., Tanabe, H., Kimura-Someya, T., Shirouzu, M., et al. (2013) · Nature · doi:10.1038/nature12656 · Cited by 757 · cited 1×
“Therefore, oral AdipoR agonists may represent a valid therapeutic approach [65].”
BackgroundDefective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis.
Pérez-Carreras, M., Del Hoyo, P., Martín, M. A., Rubio, J. C., Martín, A., Castellano, G., Colina, F., Arenas, J., & Solis-Herruzo, J. A. (2003) · Hepatology · doi:10.1002/hep.1840380426 · Cited by 734 · cited 1×
“Indeed, NASH patients present hepatic mitochondrial abnormalities, most likely related to liver fibrosis [118] These include a higher loss of protons by the electrons transport chain, due to an increased expression of mitochondrial uncoupling protein 2 (MUCP-2), a depletion of mitochondrial DNA and an abnormal oxide-r…”
BackgroundPerry, R. J., Camporez, J.-P. G., Kursawe, R., Titchenell, P. M., Zhang, D., Perry, C. J., Jurczak, M. J., Abudukadier, A., Han, M. S., Zhang, X.-M., et al. (2015) · Cell · doi:10.1016/j.cell.2015.01.012 · Cited by 719 · cited 2×
“Finally, IL-6 activates the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB)-c-Jun N-terminal kinase (JNK)-ceramide pathways, which inhibit insulin signaling and, in turn, they increase the transcription of gluconeogenic protein [50].”
BackgroundCurat, C. A., Wegner, V., Sengenès, C., Miranville, A., Tonus, C., Busse, R., & Bouloumié, A. (2006) · Diabetologia · doi:10.1007/s00125-006-0173-z · Cited by 693
Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease
Kumashiro, N., Erion, D. M., Zhang, D., Kahn, M., Beddow, S. A., Chu, X., Still, C. D., Gerhard, G. S., Han, X., Dziura, J., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1113359108 · Cited by 585
A high-fat diet is associated with endotoxemia that originates from the gut
Pendyala, S., Walker, J. M., & Holt, P. R. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.01.034 · Cited by 546 · cited 3×
“Patatin-like phospholipase domain-containing protein 3 (PNPLA3), TM6SF2 and apolipoprotein C3 (APOC3) So far, it seems clear that IR plays a key role in worsening both T2DM and NAFLD.”
BackgroundDissociation of Hepatic Steatosis and Insulin Resistance in Mice Overexpressing DGAT in the Liver
Monetti, M., Levin, M. C., Watt, M. J., Sajan, M. P., Marmor, S., Hubbard, B. K., Stevens, R. D., Bain, J. R., Newgard, C. B., Farese, R. V., et al. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.05.005 · Cited by 511 · cited 1×
“First, numerous rodent models have developed liver steatosis without IR, albeit rather due to the inhibition of VLDL efflux by MCD diet [145], an increased in fatty acids storage by DGAT overexpression [146] and inhibition of triglycerides hydrolysis by CGI-58 knockdown (a triglycerides lipase activator) [147].”
BackgroundLuukkonen, P. K., Zhou, Y., Sädevirta, S., Leivonen, M., Arola, J., Orešič, M., Hyötyläinen, T., & Yki-Järvinen, H. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.01.002 · Cited by 461
Adipose tissue as an immunological organ
Grant, R. W., & Dixit, V. D. (2015) · Obesity · doi:10.1002/oby.21003 · Cited by 453 · cited 1×
“In addition to adipokines, adipose tissue also contains many immune cells, such as macrophages, B and T cells, and neutrophils which, in case of obesity, may trigger a chronic low-grade inflammation, capable to triggering changes in the production of adipokines and, therefore, in the metabolic regulation of adipose ti…”
BackgroundThe CardioMetabolic Health Alliance
Sperling, L. S., Mechanick, J. I., Neeland, I. J., Herrick, C. J., Després, J.-P., Ndumele, C. E., Vijayaraghavan, K., Handelsman, Y., Puckrein, G. A., Araneta, M. R. G., et al. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.06.1328 · Cited by 294
Circulating leptin in non-alcoholic fatty liver disease: A systematic review and meta-analysis
Polyzos, S. A., Aronis, K. N., Kountouras, J., Raptis, D. D., Vasiloglou, M. F., & Mantzoros, C. S. (2016) · Diabetologia · doi:10.1007/s00125-015-3769-3 · Cited by 248
Leroux, A., Ferrere, G., Godie, V., Cailleux, F., Renoud, M.-L., Gaudin, F., Naveau, S., Prévot, S., Makhzami, S., Perlemuter, G., et al. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.02.028 · Cited by 246
Leptin in nonalcoholic fatty liver disease: A narrative review
Polyzos, S. A., Kountouras, J., & Mantzoros, C. S. (2015) · Metabolism · doi:10.1016/j.metabol.2014.10.012 · Cited by 235 · cited 1×
“At low levels it exerts a protective role on hepatic steatosis, due to its insulin-sensitizing effects, suppression of gluconeogenesis, de novo lipogenesis, as well as by stimulating FFAs beta-oxidation [77].”
BackgroundLiver ATP Synthesis Is Lower and Relates to Insulin Sensitivity in Patients With Type 2 Diabetes
Schmid, A. I., Szendroedi, J., Chmelik, M., Krššák, M., Moser, E., & Roden, M. (2011) · Diabetes Care · doi:10.2337/dc10-1076 · Cited by 212
Abnormal Hepatic Energy Homeostasis in Type 2 Diabetes†
Szendroedi, J., Chmelik, M., Schmid, A. I., Nowotny, P., Brehm, A., Krssak, M., Moser, E., & Roden, M. (2009) · Hepatology · doi:10.1002/hep.23093 · Cited by 204 · cited 1×
“Impaired hepatic energy metabolism and IR could prevent NASH development [115].”
BackgroundHepatocyte CYP2E1 overexpression and steatohepatitis lead to impaired hepatic insulin signaling
Schattenberg, J. M., Wang, Y., Singh, R., Rigoli, R. M., & Czaja, M. J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m410310200 · Cited by 194 · cited 1×
“Once activated, CYP2E1 contributes to the pathogenesis of NASH by producing ROS which, in turn, undermine the insulin signaling pathway by inhibiting IRS-1 and IRS-2, then downstream enzymes, including PKB, glycogen synthase 3 and FOXO1A [135].”
BackgroundFarrell, G. C., Haczeyni, F., & Chitturi, S. (2018) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-10-8684-7_3 · Cited by 178 · cited 1×
“MS attempts to worsen the condition of the liver to steatohepatitis (NASH), mainly due to lipotoxicity [32].”
BackgroundHepatic insulin signalling is dispensable for suppression of glucose output by insulin in vivo
Titchenell, P. M., Chu, Q., Monks, B. R., & Birnbaum, M. J. (2015) · Nature Communications · doi:10.1038/ncomms8078 · Cited by 169 · cited 1×
“Briefly, the consequences of insulin on glucose and lipid metabolism are: (1) increased glycogen synthesis, reduced gluconeogenesis and glycogenolysis, resulting in an increase in the amount of glycogen, and (2) increased lipogenesis and decreased lipolysis with an increase in the level of triglycerides [48].”
Background
Cited by
Lopez-Jimenez, F., Almahmeed, W., Bays, H., Cuevas, A., Di Angelantonio, E., le Roux, C. W., Sattar, N., Sun, M. C., Wittert, G., Pinto, F. J., et al. (2022) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwac187 · Cited by 362
Guo, W., Song, Y., Sun, Y., Du, H., Cai, Y., You, Q., Fu, H., & Shao, L. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1071465 · Cited by 335
Nevola, R., Epifani, R., Imbriani, S., Tortorella, G., Aprea, C., Galiero, R., Rinaldi, L., Marfella, R., & Sasso, F. C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021703 · Cited by 286
Self-citationSingh, A., Sohal, A., & Batta, A. (2024) · World Journal of Gastroenterology · doi:10.3748/wjg.v30.i48.5205 · Cited by 52
Korakas, E., Kountouri, A., Pavlidis, G., Oikonomou, E., Vrentzos, E., Michalopoulou, E., Tsigkou, V., Katogiannis, K., Pliouta, L., Balampanis, K., et al. (2024) · Journal of the Endocrine Society · doi:10.1210/jendso/bvae122 · Cited by 18
Metadata
- Authors
- Acierno, C., Caturano, A., Pafundi, P. C., Nevola, R., Adinolfi, L. E., & Sasso, F. C.
- Venue
- Exploration of Medicine
- Publisher
- Open Exploration Publishing
- Published
- 2020-09-10
- Volume
- 1
- Issue
- 5
- ISSN
- 2692-3106 (ISSN-L)
- OpenAlex
- W3086146361
- Cited by
- 73
- References
- 42
- FWCI
- 5.99
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.